Atovaquone-proguanil: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New page: '''Atovaquone-proguanil''', made by Smith Kline Glaxo and approved by the U.S. Food and Drug Administration in 2000, is a fixed-combination antimalarial drug for [[chemoprophyl...) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
'''Atovaquone-proguanil''', made by [[Smith Kline Glaxo]] and approved by the U.S. [[Food and Drug Administration]] in 2000, is a fixed-combination [[antimalarial]] drug for [[chemoprophylaxis]] and treatment. | '''Atovaquone-proguanil''', made by [[Smith Kline Glaxo]] and approved by the U.S. [[Food and Drug Administration]] in 2000, is a fixed-combination [[antimalarial]] drug for [[chemoprophylaxis]] and treatment. | ||
==Mechanism of action== | ==Mechanism of action== | ||
The two components block with two different pathways involved in the biosynthesis of [[pyrimidine]]s required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a [[ | The two components block with two different pathways involved in the biosynthesis of [[pyrimidine]]s required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a [[tetrahydrofolate dehydrogenase]] inhibitor]]. Inhibition of tetrahydrofolate dehydrogenase in ''Plasmodium sp.'' disrupts deoxythymidylate synthesis.<ref>{{citation | ||
| url = http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=634 | | url = http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=634 | ||
| title = Drug Name: Malarone (atovaquone; proguanil hydrochloride) Tablet | | title = Drug Name: Malarone (atovaquone; proguanil hydrochloride) Tablet | ||
Revision as of 13:11, 27 May 2010
Atovaquone-proguanil, made by Smith Kline Glaxo and approved by the U.S. Food and Drug Administration in 2000, is a fixed-combination antimalarial drug for chemoprophylaxis and treatment.
Mechanism of action
The two components block with two different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a tetrahydrofolate dehydrogenase inhibitor]]. Inhibition of tetrahydrofolate dehydrogenase in Plasmodium sp. disrupts deoxythymidylate synthesis.[1]
Drug-drug interactions
There are adverse interactions with tetracycline, metoclopramide and rifampin.